SANDI NAHRIRI: Open Payments
NPI 1043790587 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$245 in 11 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $245
Food & beverage: $245
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Novartis Pharmaceuticals Corporation | 1 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $22 |
| Tris Pharma Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
Products named: SPRAVATO, CAPLYTA, HETLIOZ, Quviviq, Dyanavel XR, LOREEV XR, ABILIFY ASIMTUFII, REXULTI.
Industry payments across NE — which companies pay providers there.
